Clearmind Medicine Inc (CMND)

$2.45 +0.01 (0.41%)
Market Cap 3.66M
Revenue (ttm) 0.00
Net Income (ttm) -5.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,265,100
Avg Vol 502,087
Day's Range N/A - N/A
Shares Out 1.50M
Stochastic %K 68%
Beta 1.36
Analysts Strong Buy
Price Target N/A

Company Profile

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. The company develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well...

Industry: Biotechnology
Sector: Healthcare
Phone: 973 536 1016
Address:
1220 West 6th Avenue, Suite 101, Vancouver, Canada
JohnTrack
JohnTrack Jan. 15 at 6:52 AM
$CMND quick headline, grab link... https://www.rapidticker.com/news/cmnd-sec-filing-ca4c04
0 · Reply
Annet_why_net
Annet_why_net Jan. 14 at 9:36 PM
$CMND 😄
0 · Reply
Annet_why_net
Annet_why_net Jan. 14 at 7:51 PM
$CMND Well, let's test the theory: if you're getting bored, something is definitely about to happen🙃 Bets are in: are we the hammer or the nail? Offerings are behind us. We're compliant, the reverse split is over, and with a 1.5M float, this thing is primed. Looks like a win, but keep your helmets on! (АН/РМ)🤞
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Jan. 14 at 7:10 PM
$CMND 2 hours was 1pm EST. Will it be today or in a future date?
0 · Reply
www_larval_com
www_larval_com Jan. 14 at 6:12 PM
Dumbo reporting in! $CMND just slipped -6% lower to -13% (~1Mv) a moment ago, follow for more volatility.
0 · Reply
BioTuesdays
BioTuesdays Jan. 14 at 4:19 PM
$CMND has announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100—the company’s proprietary MEAI-based oral drug candidate—for the treatment of alcohol use disorder (AUD) https://biotuesdays.com/2026/01/14/clearmind-achieves-100-treatment-success-in-second-cohort-of-cmnd-100-trial-in-aud/
0 · Reply
Annet_why_net
Annet_why_net Jan. 14 at 4:10 PM
$CMND 👀
0 · Reply
STOCK_7
STOCK_7 Jan. 14 at 3:55 PM
$CMND The party hasn't started yet, good news! He'll reach the moon in two hours! 🚀 🚀🚀
0 · Reply
swingzking
swingzking Jan. 14 at 3:46 PM
$CMND Im not convinced this is over, technicals still look good and setting up for a move. Holding
0 · Reply
STKH
STKH Jan. 14 at 3:31 PM
$CMND
0 · Reply
Latest News on CMND
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Jan 14, 2026, 8:55 AM EST - 23 hours ago

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 31, 2025, 9:10 AM EST - 14 days ago

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Dec 24, 2025, 9:15 AM EST - 21 days ago

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Dec 16, 2025, 8:45 AM EST - 4 weeks ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Dec 12, 2025, 8:32 AM EST - 4 weeks ago

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Dec 12, 2025, 6:32 AM EST - 4 weeks ago

Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Dec 10, 2025, 4:15 PM EST - 5 weeks ago

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Dec 5, 2025, 5:00 PM EST - 5 weeks ago

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Dec 2, 2025, 7:57 AM EST - 6 weeks ago

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Dec 1, 2025, 8:56 AM EST - 6 weeks ago

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

Nov 25, 2025, 7:17 AM EST - 7 weeks ago

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

Nov 24, 2025, 8:51 AM EST - 7 weeks ago

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

Nov 20, 2025, 6:01 AM EST - 2 months ago

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 19, 2025, 8:30 AM EST - 2 months ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

SPRC

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Nov 18, 2025, 8:56 AM EST - 2 months ago

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 17, 2025, 7:55 AM EST - 2 months ago

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Nov 13, 2025, 8:54 AM EST - 2 months ago

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

Nov 12, 2025, 6:25 AM EST - 2 months ago

Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Nov 10, 2025, 8:07 AM EST - 2 months ago

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Nov 6, 2025, 4:02 PM EST - 2 months ago

Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing

Nov 5, 2025, 6:55 AM EST - 2 months ago

Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Oct 30, 2025, 7:55 AM EDT - 2 months ago

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar

Oct 28, 2025, 8:08 AM EDT - 2 months ago

Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Oct 27, 2025, 9:22 AM EDT - 2 months ago

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Oct 21, 2025, 7:25 AM EDT - 3 months ago

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Oct 20, 2025, 7:41 AM EDT - 3 months ago

Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Clearmind Medicine's Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies

Sep 25, 2025, 7:40 AM EDT - 4 months ago

Clearmind Medicine's Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies

Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities

Sep 19, 2025, 8:20 AM EDT - 4 months ago

Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities

Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Aug 7, 2025, 7:32 AM EDT - 5 months ago

Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Aug 5, 2025, 8:15 AM EDT - 5 months ago

Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Jul 30, 2025, 8:18 AM EDT - 6 months ago

Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder

Jul 23, 2025, 8:55 AM EDT - 6 months ago

Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder

Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled

Jul 15, 2025, 8:05 AM EDT - 6 months ago

Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

Jul 3, 2025, 8:47 AM EDT - 7 months ago

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder

Jun 30, 2025, 9:16 AM EDT - 7 months ago

Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market

Jun 27, 2025, 9:00 AM EDT - 7 months ago

Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market

Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment

Jun 25, 2025, 7:48 AM EDT - 7 months ago

Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment

Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics

Jun 24, 2025, 8:06 AM EDT - 7 months ago

Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics

Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder

Jun 23, 2025, 7:55 AM EDT - 7 months ago

Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

Jun 12, 2025, 9:25 AM EDT - 7 months ago

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment

Jun 5, 2025, 7:32 AM EDT - 8 months ago

Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

May 20, 2025, 9:00 AM EDT - 8 months ago

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Apr 25, 2025, 7:59 AM EDT - 9 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

SPRC

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Apr 25, 2025, 7:55 AM EDT - 9 months ago

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites

Apr 23, 2025, 8:25 AM EDT - 9 months ago

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior

Apr 17, 2025, 7:38 AM EDT - 9 months ago

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism

Apr 16, 2025, 8:40 AM EDT - 9 months ago

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder

Apr 10, 2025, 8:25 AM EDT - 10 months ago

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Apr 8, 2025, 6:55 AM EDT - 10 months ago

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment

Apr 1, 2025, 8:15 AM EDT - 10 months ago

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment

JohnTrack
JohnTrack Jan. 15 at 6:52 AM
$CMND quick headline, grab link... https://www.rapidticker.com/news/cmnd-sec-filing-ca4c04
0 · Reply
Annet_why_net
Annet_why_net Jan. 14 at 9:36 PM
$CMND 😄
0 · Reply
Annet_why_net
Annet_why_net Jan. 14 at 7:51 PM
$CMND Well, let's test the theory: if you're getting bored, something is definitely about to happen🙃 Bets are in: are we the hammer or the nail? Offerings are behind us. We're compliant, the reverse split is over, and with a 1.5M float, this thing is primed. Looks like a win, but keep your helmets on! (АН/РМ)🤞
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Jan. 14 at 7:10 PM
$CMND 2 hours was 1pm EST. Will it be today or in a future date?
0 · Reply
www_larval_com
www_larval_com Jan. 14 at 6:12 PM
Dumbo reporting in! $CMND just slipped -6% lower to -13% (~1Mv) a moment ago, follow for more volatility.
0 · Reply
BioTuesdays
BioTuesdays Jan. 14 at 4:19 PM
$CMND has announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100—the company’s proprietary MEAI-based oral drug candidate—for the treatment of alcohol use disorder (AUD) https://biotuesdays.com/2026/01/14/clearmind-achieves-100-treatment-success-in-second-cohort-of-cmnd-100-trial-in-aud/
0 · Reply
Annet_why_net
Annet_why_net Jan. 14 at 4:10 PM
$CMND 👀
0 · Reply
STOCK_7
STOCK_7 Jan. 14 at 3:55 PM
$CMND The party hasn't started yet, good news! He'll reach the moon in two hours! 🚀 🚀🚀
0 · Reply
swingzking
swingzking Jan. 14 at 3:46 PM
$CMND Im not convinced this is over, technicals still look good and setting up for a move. Holding
0 · Reply
STKH
STKH Jan. 14 at 3:31 PM
$CMND
0 · Reply
STKH
STKH Jan. 14 at 3:29 PM
$CMND 5$ AH
0 · Reply
Rachs88
Rachs88 Jan. 14 at 3:11 PM
$CMND reversal is imminent, it's one of those stocks that will run after hours. Mark it
0 · Reply
Trabetrash
Trabetrash Jan. 14 at 3:02 PM
$CMND scam
0 · Reply
Trabetrash
Trabetrash Jan. 14 at 3:02 PM
$CMND
0 · Reply
Trabetrash
Trabetrash Jan. 14 at 3:01 PM
$CMND
0 · Reply
Trabetrash
Trabetrash Jan. 14 at 2:38 PM
$CMND scam pump and dump
0 · Reply
Trabetrash
Trabetrash Jan. 14 at 2:38 PM
$CMND dump!!!!!
0 · Reply
Trabetrash
Trabetrash Jan. 14 at 2:22 PM
$CMND dump
0 · Reply
Surfude
Surfude Jan. 14 at 2:18 PM
$CMND above 3.28 we're in the GAP--easy rid to 4
0 · Reply
MrTicker
MrTicker Jan. 14 at 2:15 PM
$CMND solid news, pullback to load, volume still low, break $2.85 to test $3+
0 · Reply
Trabetrash
Trabetrash Jan. 14 at 2:11 PM
$CMND pump and dump rip
0 · Reply
swingzking
swingzking Jan. 14 at 2:11 PM
$CMND Low float and high volume= technicals can change in a flash
0 · Reply